This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of ME-401 in Subjects With Relapsed/Refractory CLL/SLL or FL

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by MEI Pharma, Inc.
Clinipace LTD
Information provided by (Responsible Party):
MEI Pharma, Inc. Identifier:
First received: September 12, 2016
Last updated: August 14, 2017
Last verified: September 2016
The purpose of this study is to determine the minimum biologically effective dose of ME-401; determine the maximally tolerated dose of ME-401 and determine the dose limiting toxicities of ME-401. Secondary objectives to evaluate the safety profile and efficacy of ME-401.

Condition Intervention Phase
Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma Follicular Lymphoma Drug: ME-401 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL)

Resource links provided by NLM:

Further study details as provided by MEI Pharma, Inc.:

Primary Outcome Measures:
  • Minimum Biologically Effective Dose (mBED) of ME-401 [ Time Frame: 1 year ]
    The mBED will be defined as the dose that is safe and that achieves an objective response rate

  • Maximally Tolerated Dose (MTD) of ME-401 [ Time Frame: 1 year ]
    The MTD will be determined as the dose level with a DLT rate closest to .25

  • Dose Limiting Toxicities (DLTs) of ME-401 [ Time Frame: within the first 56 days ]
    DLTs will be measured by the number of AEs that occur within the first 56 days of ME-401 administration, is considered clinically significant by the P.I. and occurs in the presence of supportive care

Secondary Outcome Measures:
  • Safety profile of ME-401 [ Time Frame: 1 year ]
    Safety profile will be measured by number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  • The Recommended Phase 2 Dose (RP2D) [ Time Frame: 2 year ]
    The RP2D will be determined by the evaluation of safety and efficacy data

  • Peak Plasma Concentration (Cmax) [ Time Frame: 2 years ]
  • AUC (area under the concentration time curve) [ Time Frame: 2 years ]
  • Efficacy of ME-401 [ Time Frame: 2 years ]
    The efficacy of ME-401 assessed by the overall response (OR)

  • Efficacy of ME-401 [ Time Frame: 2 years ]
    Efficacy of ME-401 assessed by complete response (CR)

  • Efficacy of ME-401 [ Time Frame: 2 years ]
    Efficacy of ME-401 assessed by minimal residual disease negativity (MRD)

  • Efficacy of ME-401 [ Time Frame: 2 years ]
    Efficacy of ME-401 assessed by progression-free survival (PFS)

Estimated Enrollment: 84
Study Start Date: October 2016
Estimated Study Completion Date: July 2020
Estimated Primary Completion Date: March 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ME-401 Drug: ME-401

Detailed Description:

This is a Phase 1b, open-label, dose escalation/expansion study with seven planned dose levels (Cohorts) of ME-401. DLT will be assessed within the first 56 days (8 weeks). A Continual Reassessment Method (CRM) model will be used to determine dose escalation/de-escalation.

Dose levels will consist of 6 subjects and can be expanded to enroll up to 12 subjects. The total number of cohorts depends on the incidence of DLTs.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of relapsed/refractory CLL and/or relapsed/refractory SLL or FL
  • No prior therapy with PI3Kd inhibitors
  • No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was intolerant of BTK therapy
  • QT-interval corrected according to Fridericia's formula (QTcF) ≤ 450 milliseconds (ms)
  • For females of childbearing potential, a negative serum pregnancy test within 14 days of study Day 0

Exclusion Criteria:

  • Known histological transformation from CLL to an aggressive lymphoma
  • Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
  • Subjects who have tested positive for hepatitis B surface antigen and/or hepatitis B core antibody
  • Positive for hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) antibody
  • Ongoing drug-induced pneumonitis
  • History of clinically significant cardiovascular abnormalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02914938

Contact: Lisa McColley 402-238-2615
Contact: Todd Butler (MEI) 858-369-7129

United States, California
Compassionate Care Not yet recruiting
Corona, California, United States, 92708
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Stony Brook Recruiting
Stony Brook, New York, United States, 11794
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
United States, Oklahoma
Stephenson Cancer Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
St. Luke's Recruiting
Bethlehem, Pennsylvania, United States, 18015
United States, Tennessee
Vanderbilt Not yet recruiting
Nashville, Tennessee, United States, 37240
United States, Washington
Swedish Cancer Center Recruiting
Seattle, Washington, United States, 98104
United States, Wisconsin
Carbone Cancer Center Recruiting
Madison, Wisconsin, United States, 53792
lstituto Oncologico della Svizzera ltaliana Ospedale Regionale Bellinzona e Valli CH Recruiting
Bellinzona, Switzerland
Sponsors and Collaborators
MEI Pharma, Inc.
Clinipace LTD
Study Director: Richard Ghalie (MEI Pharma, Inc.), MD Senior Vice President, Clinical Development
Study Chair: Andrew D Zelenetz, M.D. Ph.D Vice Chair, Medical Informatics Memorial Sloan Kettering
  More Information

Responsible Party: MEI Pharma, Inc. Identifier: NCT02914938     History of Changes
Other Study ID Numbers: ME-401-002
Study First Received: September 12, 2016
Last Updated: August 14, 2017

Additional relevant MeSH terms:
Lymphoma, Follicular
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Leukemia, B-Cell processed this record on August 22, 2017